; Illicit and licit drugs are routinely used during pregnancy without the necessary pharmacokinetics, efficacy, or safety data. P-gp and BCRP are the two major ABC efflux transporters in the placenta that limit fetal exposure to drugs. The levels of P-gp and BCRP in the placenta change with gestation;however, how the changes in transporter expression affect fetal drug exposure over gestation is still poorly understood. Thus, the goal of this project is to assess the role of placental P-gp and BCRP in fetal drug exposure over gestation and elucidate the mechanisms by which P-gp and BCRP in the placenta are regulated during pregnancy. We have shown that progesterone strongly induces BCRP in BeWo cells via progesterone receptor B (PRB). Another related and important, but yet unanswered question is whether expression and activity of placental P-gp and BCRP can be altered by exposure to drugs through inhibition or induction. We hypothesize that expression and activity of placental P-gp and BCRP change with gestation through regulation by pregnancy hormones, growth factors, and retinoic acid as well as by drugs and xenobiotics. To test these hypotheses, we propose the following specific aims. We will determine 1) the effects of drug-drug interactions on fetal exposure to a P-gp (norbuprenorphine), a BCRP (nitrofurantoin), or a dual P-gp/BCRP (bupropion) substrate in FVB mice at two different gestational ages with and without a P-gp (nelfinavir), a BCRP (pantoprazole), or a dual P-gp/BCRP (elacridar) inhibitor, respectively;2) if/n vitro expression and activity of P-gp and BCRP in primary human trophoblasts (from early, mid, and term placenta) are altered by the treatment with PXR (e.g., HIV protease inhibitors, methadone, St John's wort, and buprenorphine), CAR (e.g., phenobarbital, phenytoin and diazepam), AhR (e.g., omeprazole and benezo[a]pyrene) or PPARy (e.g., some NSAIDs) ligands at clinically relevant plasma concentrations, and elucidate the mechanisms of changes in expression observed;3a) if in vitro expression and activity of P-gp and BCRP in primary human trophoblasts (from early, mid, and term placenta) are regulated by pregnancy hormones (e.g., progesterone, 17|3-estradiol, Cortisol, placental growth hormone), growth factors (e.g., epidermal growth factor and insulin-like growth factors), and all-trans retinoic acid, individually and in combination, at plasma concentrations observed during pregnancy, and elucidate the mechanisms of changes in expression observed;3b) if progesterone regulates In vivo expression and activity of placental Bcrpi through PRB. We will measure expression and in vivo activity of placental Bcrp1 in PRB-/- pregnant mice compared with those in wild-type pregnant mice.

Public Health Relevance

Completion ofthe proposed studies will lead to a more comprehensive and advanced understanding ofthe mechanism by which fetal exposure to illicit and licit drugs is mediated by the ATP-binding cassette efflux drug transporters P-gp and BCRP in the placenta during pregnancy. Results obtained from these studies will help the clinicians and the regulators to optimize and better guide drug therapy in pregnant women.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
5P01DA032507-02
Application #
8726364
Study Section
Special Emphasis Panel (ZRG1-DKUS-C)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
2
Fiscal Year
2014
Total Cost
$289,717
Indirect Cost
$95,977
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Wagner, David J; Hu, Tao; Wang, Joanne (2016) Polyspecific organic cation transporters and their impact on drug intracellular levels and pharmacodynamics. Pharmacol Res 111:237-46
Prasad, Bhagwat; Johnson, Katherine; Billington, Sarah et al. (2016) Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics. Drug Metab Dispos 44:1920-1924
Prasad, B; Gaedigk, A; Vrana, M et al. (2016) Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther 100:362-70
Farooq, Muhammad; Kelly, Edward J; Unadkat, Jashvant D (2016) CYP2D6 Is Inducible by Endogenous and Exogenous Corticosteroids. Drug Metab Dispos 44:750-7
Patilea-Vrana, G; Unadkat, J D (2016) Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model. Clin Pharmacol Ther 100:413-418
Sager, Jennifer E; Price, Lauren S L; Isoherranen, Nina (2016) Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro. Drug Metab Dispos 44:1709-19
Zhang, Zufei; Farooq, Muhammad; Prasad, Bhagwat et al. (2015) Prediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes. Drug Metab Dispos 43:836-42
Mao, Qingcheng; Unadkat, Jashvant D (2015) Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J 17:65-82
Sager, Jennifer E; Yu, Jingjing; Ragueneau-Majlessi, Isabelle et al. (2015) Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metab Dispos 43:1823-37
Stieger, Bruno; Unadkat, Jashvant D; Prasad, Bhagwat et al. (2014) Role of (drug) transporters in imaging in health and disease. Drug Metab Dispos 42:2007-15